Recent Updates
Recently added Catalysts

Commercially available combination of dutasteride and tamsulosin

Phase 1

Urologic Diseases | Small molecule | Nephrology |GSK plc|Last Updated: Sep 13, 2018

Target and mechanism

ModalitySmall molecule

Also known as commercially available dutasteride

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLED
Total Trials2
Total Enrollment155

FDA Designations

No designations recorded

Clinical trial landscape

Commercially available combination of dutasteride and tamsulosin · 2 trials · 1 indication

Phase 1 2
NCT02052713Bioequivalence Study of the Second Generation Dutasteride and Tamsulosin Hydrochloride (HCL) Combination Capsule in Fasted StateUrologic Diseases
COMPLETED78 Analytics
NCT02058576Bioequivalence Study of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in Fed StateUrologic Diseases
COMPLETED77 Analytics
PHASE1COMPLETED
Bioequivalence Study of the Second Generation Dutasteride and Tamsulosin Hydrochloride (HCL) Combination Capsule in Fasted State
Urologic DiseasesUnlock trial analytics
PHASE1COMPLETED
Bioequivalence Study of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in Fed State
Urologic DiseasesUnlock trial analytics

Study Endpoints

Primary Endpoints

Pharmacokinetic (PK) profile of second generation dutasteride when co-administered with tamsulosin HCL relative to the commercial combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg in the fed state to investigate bioequivalence
PK blood samples will be collected at pre-dose, 0, 0.25, 0.50, 0.75, 1, 2, 3, 4, 5, 6, 6.5, 7, 7.5, 8, 10, 12, 16, 24, 48, 72 hour post dose in each period.

PK parameters include: area under the concentration-time curve from time zero to last time of quantifiable concentration within a subject (AUC \[0-t\]), and maximum observed concentration (Cmax) as data permit

Composite of PK parameters for tamsulosin HCl when it is co-administered with second generation dutasteride relative to the currently available commercial dutasteride 0.5 mg + tamsulosin HCL 0.4 mg in the fed state to investigate bioequivalence
PK blood samples will be collected at pre-dose, 0, 0.25, 0.50, 0.75, 1, 2, 3, 4, 5, 6, 6.5, 7, 7.5, 8, 10, 12, 16, 24, 48, 72 hour post dose in each period.

PK parameters include: AUC\[0-t\]), area under the concentration-time curve from time zero extrapolated to infinite time (AUC\[0-infinity\]) \[defaulting to AUC(0-t)

Pharmacokinetic profile for second generation dutasteride when co-administered with tamsulosin HCL relative to the currently available commercial combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg in the fed state to investigate bioequivalence
PK blood samples will be collected at pre-dose, 0, 0.25, 0.50, 0.75, 1, 2, 3, 4, 5, 6, 6.5, 7, 7.5, 8, 10, 12, 16, 24, 48, 72 hour post dose in each period.

PK parameters include: area under the concentration-time curve from time zero to last time of quantifiable concentration within a subject (AUC \[0-t\]), and maximum observed concentration (Cmax) as data permit.

Composite of PK parameters for tamsulosin HCL when it is co-adminstered with second generation dutasteride relative to the currently available commercial dutasteride 0.5 mg and tamsulosin HCL 0.4 mg in the fed state to investigate bioequivalence
PK blood samples will be collected at pre-dose, 0, 0.25, 0.50, 0.75, 1, 2, 3, 4, 5, 6, 6.5, 7, 7.5, 8, 10, 12, 16, 24, 48, 72 hour post dose in each period.

PK parameters include: AUC\[0-t\]), area under the concentration-time curve from time zero extrapolated to infinite time (AUC\[0-infinity\]) \[defaulting to AUC(0-t)

Secondary Endpoints

PK profile of dutasteride
PK blood samples will be collected at pre-dose, 0, 0.25, 0.50, 0.75, 1, 2, 3, 4, 5, 6, 6.5, 7, 7.5, 8, 10, 12, 16, 24, 48, 72 hour post dose in each period.
PK profile of tamsulosin HCl
PK blood samples will be collected at pre-dose, 0, 0.25, 0.50, 0.75, 1, 2, 3, 4, 5, 6, 6.5, 7, 7.5, 8, 10, 12, 16, 24, 48, 72 hour post dose in each period.
Clinically significant changes in Vital signs measurements to assess safety and tolerability
Baseline (screening) and up to 33 days.
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeOTHER

Treatment Arms

ArmTypeDescription
Sequence ABEXPERIMENTALSubjects will receive Treatment A (commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg) in period 1 and Treatment B (combination of second generation dutasteride 0.5 mg and tamsulosin HCl 0.4 mg combination) in period 2 orally once daily under fasted condition.
Sequence BAEXPERIMENTALSubjects will be randomized to receive Treatment B (combination of second generation dutasteride 0.5 mg and tamsulosin HCl 0.4 mg combination) in period 1 and Treatment A (commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg) in period 2 orally once daily under fasted condition.\[dutasteride 0.5 mg and tamsulosin HCl 0.4 mg) in period 2 orally once daily under fasted condition.

Interventions

NameTypeDescription
Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mgDRUGCommercially available, orange and brown, hard shell capsule, administered orally as a single dose on Day 1 under fasted condition.
Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsuleDRUGOrange and brown, hard shell capsule, administered orally, as a single-dose on Day 1 under fasted condition.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 50 Years
SexMALE
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Males who are 18 to 50 years of age, inclusive. * Weight range 55 to 95 kg (inclusive) and body mass index (BMI) 18 to 30 kilogram/meter\^2 (kg/m\^2) (inclusive). * Healthy subjects defined as individuals who are free from clinically significant illness or disease as determine...

Countries:United Kingdom
Unlock Eligibility Criteria